Rhythm Pharmaceuticals, Inc. RYTM Increase Decrease In Derivative Liabilities
Increase Decrease In Derivative Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDerivativeLiabilities.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported increase decrease in derivative liabilities of $330K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities increased by 312.5% year-over-year, from $80K to $330K.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities?
- Over 2 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities has grown at a 90.8% compound annual growth rate (CAGR), from -$250K to -$910K.
- What does increase decrease in derivative liabilities mean?
- This measures the net change in liabilities arising from derivative financial instruments held by the company. It reflects fluctuations in the fair value of these instruments that impact the company's overall risk profile.